Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study.
Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: the OXEL study.
- 2019
MedStar Georgetown University Hospital Residents
Poster presented at
MedStar Georgetown University Hospital Residents
Poster presented at